Valuation: Daxor Corporation

Market Cap 60.89M 53.48M 49.74M 45.64M 85.76M 5.86B 87.08M 591M 231M 2.88B 229M 224M 9.97B P/E 2026 *
-49.8x
P/E 2027 * -348x
Enterprise Value 60.89M 53.48M 49.74M 45.64M 85.76M 5.86B 87.08M 591M 231M 2.88B 229M 224M 9.97B EV / Sales 2026 *
5.12x
EV / Sales 2027 * 2.93x
Free-Float
46.74%
Yield 2026 *
-
Yield 2027 * -
1 day+1.86%
1 week-1.79%
Current month+3.98%
1 month+1.95%
3 months+4.44%
6 months-14.97%
Current year-27.42%
1 week 10.4
Extreme 10.4001
11.09
1 month 9.86
Extreme 9.86
11.97
Current year 8.56
Extreme 8.56
14.75
1 year 8.56
Extreme 8.56
14.76
3 years 6.55
Extreme 6.55
14.76
5 years 6.55
Extreme 6.55
14.76
10 years 3.4
Extreme 3.4001
24.08
Manager TitleAgeSince
Chief Executive Officer 56 2012-12-31
Director of Finance/CFO 69 2018-09-27
Chief Tech/Sci/R&D Officer - 2024-06-04
Director TitleAgeSince
Director/Board Member 91 1988-12-31
Chairman 56 2017-02-13
Director/Board Member 70 2016-06-21
Date Insider Type Main position Quantity % Market Cap.
6/23/26 Free

Chief Executive Officer

30,000 0.5148%
6/23/26 Free

Director

2,500 0.0429%
6/23/26 Free

Director

2,500 0.0429%
Change 5-day change 1-year change 3-year change Capi.($)
+1.86%-1.79%+7.05%+8.51% 60.89M
+0.13%+1.09%+18.53%+100.92% 14.53B
+1.08%+3.82%+41.36%+123.78% 11.83B
+1.98%-2.62%-12.32%+24.05% 8.74B
-0.25%-1.90%-16.11%-15.45% 7.4B
+0.53%+1.72%+28.18%+116.26% 7.43B
+0.42%+3.51%+15.84%+60.23% 6.49B
0.00%-1.41%+9.52%+23.36% 4.74B
+0.91%+0.27%+13.15%+7.98% 4.18B
+0.30%-1.43% - - 3.65B
Average +0.70%+0.38%+11.69%+49.96% 6.91B
Weighted average by Cap. +0.61%+0.64%+14.44%+67.66%

Financials

2026 *2027 *
Net sales 11.9M 10.45M 9.72M 8.92M 16.76M 1.15B 17.02M 115M 45.09M 563M 44.67M 43.71M 1.95B 20.8M 18.27M 16.99M 15.59M 29.29M 2B 29.74M 202M 78.82M 985M 78.08M 76.4M 3.4B
Net income -1.2M -1.05M -980K -899K -1.69M -116M -1.72M -11.64M -4.55M -56.81M -4.5M -4.41M -196M -200K -176K -163K -150K -282K -19.26M -286K -1.94M -758K -9.47M -751K -735K -32.74M
Net Debt - -
Logo Daxor Corporation
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Employees
45
Date Price Change Volume
26-07-24 US$10.45 -2.38% 710
26-07-22 US$10.71 +1.86% 335
26-07-21 US$10.51 -3.63% 4,572
26-07-20 US$10.91 +0.05% 973
26-07-17 US$10.90 +3.71% 4,771
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.45USD
Average target price
22.50USD
Spread / Average Target
+115.31%

Quarterly revenue - Rate of surprise